Table 1.
Characteristic of included studies for COVID-19 vaccines.
| ID | Country | Year | Type of surveillance | Trimes- ter |
Vaccine | Population | N (Ex/No Ex) |
Study design | Effect measures | Outcomes | Safety concerns |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pregnant persons | |||||||||||
| Bookstein 2021[31] | Israel | 2021 | Active | 1 + 2 + 3 | BNT162b2 | Pregnant p | 390 | Surveillance | IR | Mat, Neo, AEFI | No |
| Zauche 2021[85] | USA | 2020–21 | Active | 1 + 2 | BNT162b2, mRNA-1273 | Pregnant p | 2,456 | Registry | IR | Mat. | No |
| Goldshtein 2021[40] | Israel | 2020–21 | Active | 1 + 2 + 3 | BNT162b2 | Pregnant p | 15,060 (7,530/7,530) | Cohort study | IR | Mat, Neo | No |
| Gray 2021[41] | USA | 2021 | Active | 1 + 2 + 3 | BNT162b2, mRNA-1273 | Pregnant p | 84 | Cohort study | IR | Mat, Neo, AEFI | No |
| Kharbanda 2021[49] | USA | 2020 | Active | 1 + 2 | BNT162b2, mRNA-1273, Ad26.COV2.S | Pregnant p | 271,083 (20,139/250,944) |
Surveillance | IR, aOR | Mat. | No |
| Shimabukuro 2021[82] | USA | 2020–21 | Passive | 1 + 2 + 3 | BNT162b2, mRNA-1273 | Pregnant p | 19,252 (16,522/2,730) |
Registry | IR | Mat, Neo, AEFI | No |
| Blakeway 2021[87] | UK | 2021 | Active | 1 + 2 | BNT162b2, mRNA-1273, ChAdOx1 | Pregnant p | 532 (133/399) |
Cohort study | IR, aOR | Mat, Neo | No |
| Pregnant animals | |||||||||||
| Stebbings 2021[94] | UK | 2020 | NA | NA | ChAdOx1 | Animals | 50 (25/25) | Non-RCT | IR | Mat, Neo. | No |
| Bowman 2021[89] | USA | 2019- | NA | NA | BNT162b2 | Animals | 88 (44/44) | RCT | IR | Neo. | No |
NA: Not available; Pregnant p: Pregnant person; IR: Incidence rate; aOR: adjusted Odds Ratio; Mat: Maternal; Neo: Neonatal; AEFI: Adverse Event Following Immunization.